欧洲机械循环支持患者注册登记(EUROMACS):第三份儿科(Paedi-EUROMACS)报告
该报告基于EUROMACS儿科注册数据,分析2000年1月1日至2020年12月31日期间25家医院480例年龄<19岁患者的537例植入。2年随访时21.9%在支持期间死亡,12个月时45.1%接受移植、7.5%脱离设备、20.8%死亡;总体12个月生存率为79.2%,早期与后期生存率无显著差异,年龄<1岁(P=0.01)和体重<20 kg(P=0.015)患者生存率较低。
要点
- 12个月总体生存率为79.2%,12个月时45.1%接受移植、7.5%脱离设备、20.8%死亡。
- 2年随访时21.9%在支持期间死亡;6个月移植率仍低(33.2%)。
- 年龄<1岁(P=0.01)和体重<20 kg(P=0.015)患者生存率较低。
核心结论
- 心室辅助装置植入后12个月总体生存率为79.2%。
- 早期与后期生存率比较无显著差异。
- 年龄<1岁(P=0.01)和体重<20 kg(P=0.015)患者生存率较低。
- 6个月移植率仍低(33.2%)。
研究设计与样本
- 基于欧洲机械循环支持患者注册登记(EUROMACS)的第三份儿科报告。
- 参与医院提交机械循环支持植入的术前、围术期和长期术后数据。
- 分析2000年1月1日至2020年12月31日期间所有年龄<19岁患者的植入数据。
- 25家医院贡献了480例患者的537例注册植入。
主要发现
- 心力衰竭最常见病因是任何形式的心肌病(59%),其次为先天性心脏病(15%)和心肌炎(14%)。
- 竞争结局分析显示,86%存活至移植、恢复或仍在支持中;2年随访时21.9%在支持期间死亡。
- 12个月时,45.1%接受移植,7.5%脱离设备,20.8%死亡。
- 3个月不良事件率:设备故障包括泵更换为每患者年1.59次,大出血为0.7次,严重感染为0.78次,神经系统事件为0.71次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A third paediatric report has been generated from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). The purpose of EUROMACS, which is operated by the European Association for Cardio-Thoracic Surgery, is to gather data related to durable mechanical circulatory support for scientific purposes and to publish reports with respect to the course of mechanical circulatory support therapy. Since the first report issued, efforts to increase compliance and participation have been extended. Additionally, the data provided the opportunity to analyse patients of younger age and lower weight. METHODS: Participating hospitals contributed pre-, peri- and long-term postoperative data on mechanical circulatory support implants to the registry. Data for all implants in paediatric patients (<19 years of age) performed from 1 January 2000 to 31 December 2020 were analysed. This report includes updates of patient characteristics, implant frequency, outcome (including mortality rates, transplants and recovery rates) as well as adverse events including neurological dysfunction, device malfunction, major infection and bleeding. RESULTS: Twenty-five hospitals contributed 537 registered implants in 480 patients. The most frequent aetiology of heart failure was any form of cardiomyopathy (59%), followed by congenital heart disease and myocarditis (15% and 14%, respectively). Competing outcomes analysis revealed that a total of 86% survived to transplant or recovery or are ongoing; at the 2-year follow-up examination, 21.9% died while on support. At 12 months, 45.1% received transplants, 7.5% were weaned from their device and 20.8% died. The 3-month adverse events rate was 1.59 per patient-year for device malfunction including pump exchange, 0.7 for major bleeding, 0.78 for major infection and 0.71 for neurological events. CONCLUSIONS: The overall survival rate was 79.2% at 12 months following ventricular assist device implant. The comparison of survival rates of the early and later eras shows no significant difference. A focus on specific subgroups showed that survival was less in patients of younger age (<1 year of age; P = 0.01) and lower weight (<20 kg; P = 0.015). Transplant rates at 6 months continue to be low (33.2%).
引用
- de By TMMH, Schweiger M, Hussain H, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): third Paediatric (Paedi-EUROMACS) report. Eur J Cardiothorac Surg. 2022. PMID: 35758622. doi:10.1093/ejcts/ezac355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。